Botox Fda Label 2024. In phase iii clinical studies, botox demonstrated statistical significance for the. Fda approves expanded botox® (onabotulinumtoxina) label for the treatment.
Fda approves expanded botox® (onabotulinumtoxina) label for the treatment. This expanded botox ® dosing guidance provides physicians the ability to.